[Minutes, Advisory Committee to the Director GP-160 Meeting (1992: Bethesda, Maryland)]

1 each individual patient, that antibody response will
2 again be transient.
3 You will then give another dose of
4 vaccine. You may or may not see that antibody
5 response. It may be to a different epitope, and the
6 concept of are you eliciting an immuno-dominant or
7 consistent immune response, I think, is something that
8 is open for discussion; and whether that's good or
9 bad, I think, is open for discussion. Next slide.
10 I actually wanted to go to follow the --
11 compared to what, and I will not spend a lot of time
12 on this -- to some newer data, just again to follow
13 the theme as to where gp-160 fits with respect to the
14 HIV vaccine program at the AIDS Vaccine Evaluation
15 Unit:
16 These are some data from AIDS Vaccine
17 Evaluation Unit Trial 103, which is looking at this
18 nonglycocelated antigen. The only thing I would like
19 to show you is to show you that there are other
20 vaccines that are induces immune responses.
21 These are stimulation indices to the
22 antigen itself. This is a group of patients who have
NEAL R. GROSS
COURT REPORTERS AND TRANSCRIBERS
1323 RHODE ISLAND AVENUE, N.W.
[phone] WASHINGTON, D.C. 20005 [phone]